Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
09-05-01-03 Magnesium
Magnesium preparations may not be interchangeable due to differences in bioavailability, therefore caution should be exercised when switching preparations to ensure tolerability and to maintain therapeutic effect.
| Magnesium citrate |
|
Formulary
|
Tablets 4mmol First line magnesium replacement choice in patients with a bowel stoma. |
|
| Magnesium Glycerophosphate |
|
Formulary
|
Tablets 4mmol |
 NICE: Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate |
|
|
-Unlicensed| Magnesium Sulfate |
|
Formulary
|
Injection 50% (magnesium 2mmol/mL) |
|
MHRA: Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy |
|
Links
LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement- LSCMMG: Gluten-Free food products: Position Statement
- LSCMMG: Oral Nutritional Supplements in Primary Care
- LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
- MHRA: Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy
- NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE NG20: Coeliac disease: recognition, assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE: Evidence Summary: Magnesium glycerophosphate
- NICE: Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate
- SPS Q&A: Can magnesium sulphate be given subcutaneously?
- SPS Q&A: Magnesium sulphate injection: converting between millimoles, milligrams and percentage w/v.